STADA names Boris Döbler as CFO

The supervisory board of German drugmaker STADA Arzneimittel (SAZ: Xetra) has appointed Boris Döbler as group chief financial officer (CFO) with effect from January 1, 2023. Mr Döbler has been STADA’s interim CFO since August 2022.

“I am delighted that we have identified an ideal internal candidate with extensive leadership experience, deep financial knowledge and strong strategic insights into STADA’s focus areas – consumer healthcare, generics and specialty medicines,” stated STADA chief executive, Peter Goldschmidt, adding: “I am convinced that Boris’ expertise, dedication and commitment to our unique One STADA culture makes him the ideal CFO to guide and further accelerate STADA’s growth journey.”

Since joining STADA in April 2019, Mr Döbler has worked closely with commercial leaders and country heads across the group, gaining extensive experience of the group’s operations. He initially served as CFO for European Markets, before assuming the role of vice president, corporate financial planning and analysis in March 2020. In August 2022, Mr Döbler became group CFO on an interim basis. In his time at STADA, Mr Döbler’s considerable contributions have enabled STADA to consistently outperform the market, evidenced by a 23% rise in adjusted earnings before interest, tax, depreciation and amortization (EBITDA) in the first half of 2022.